623 related articles for article (PubMed ID: 27658789)
21. Molecular profiling of biliary tract cancer: a target rich disease.
Jain A; Javle M
J Gastrointest Oncol; 2016 Oct; 7(5):797-803. PubMed ID: 27747093
[TBL] [Abstract][Full Text] [Related]
22. New Horizons for Precision Medicine in Biliary Tract Cancers.
Valle JW; Lamarca A; Goyal L; Barriuso J; Zhu AX
Cancer Discov; 2017 Sep; 7(9):943-962. PubMed ID: 28818953
[TBL] [Abstract][Full Text] [Related]
23. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
[TBL] [Abstract][Full Text] [Related]
24. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
25. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
Demols A; Bucalau AM; Mans L
Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
[TBL] [Abstract][Full Text] [Related]
26. New genomic landscapes and therapeutic targets for biliary tract cancers.
Simbolo M; Fassan M; Mafficini A; Lawlor RT; Ruzzenente A; Scarpa A
Front Biosci (Landmark Ed); 2016 Jan; 21(4):707-18. PubMed ID: 26709801
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
28. Biliary tract cancer prognostic and predictive genomics.
Mondaca S; Nervi B; Pinto M; Abou-Alfa GK
Chin Clin Oncol; 2019 Aug; 8(4):42. PubMed ID: 31431036
[TBL] [Abstract][Full Text] [Related]
29. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
30. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
32. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
[TBL] [Abstract][Full Text] [Related]
33. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
34. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
35. Systemic therapy for biliary cancers.
Jordan E; Abou-Alfa GK; Lowery MA
Chin Clin Oncol; 2016 Oct; 5(5):65. PubMed ID: 27829278
[TBL] [Abstract][Full Text] [Related]
36. Genomics driven precision oncology in advanced biliary tract cancer improves survival.
Kumar-Sinha C; Vats P; Tran N; Robinson DR; Gunchick V; Wu YM; Cao X; Ning Y; Wang R; Rabban E; Bell J; Shankar S; Mannan R; Zhang Y; Zalupski MM; Chinnaiyan AM; Sahai V
Neoplasia; 2023 Aug; 42():100910. PubMed ID: 37267699
[TBL] [Abstract][Full Text] [Related]
37. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Roth GS; Verlingue L; Sarabi M; Blanc JF; Boleslawski E; Boudjema K; Bretagne-Bignon AL; Camus-Duboc M; Coriat R; Créhange G; De Baere T; de la Fouchardière C; Dromain C; Edeline J; Gelli M; Guiu B; Horn S; Laurent-Croise V; Lepage C; Lièvre A; Lopez A; Manfredi S; Meilleroux J; Neuzillet C; Paradis V; Prat F; Ronot M; Rosmorduc O; Cunha AS; Soubrane O; Turpin A; Louvet C; Bouché O; Malka D
Eur J Cancer; 2024 May; 202():114000. PubMed ID: 38493667
[TBL] [Abstract][Full Text] [Related]
38. New Treatment Options for Advanced Biliary Tract Cancer.
Mizrahi JD; Shroff RT
Curr Treat Options Oncol; 2020 Jun; 21(8):63. PubMed ID: 32602010
[TBL] [Abstract][Full Text] [Related]
39. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
[TBL] [Abstract][Full Text] [Related]
40. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
